GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms
GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms zbecker Wed, 05/01/2024 - 11:34